Eternity Healthcare, a biopharmaceutical company with technologies in diagnostics and medical devices, is currently developing a noninvasive sugar monitoring device that uses saliva instead of blood.

According to the company, the technology utilizes an ultra sensitive sugar monitor and an additional sensor for salivary amylase enzyme activity.

Eternity Healthcare CEO Dr Hassan Salari said the company will be the first company to focus on the development of an alternative saliva-based glucose monitoring test.

"Using two parameters of diabetes physiological changes, the device will provide more accurate results for diabetics and their blood sugar levels," Dr Salari added.

"This new test should reduce the patient’s reliance on the currently used painful finger pricking and blood collection method."

According to the Center for Disease Control, over ten million glucose monitor devices and several hundred million of test strips are sold annually.